Mercilon (Desogestrel, Ethinylestradiol)

The ethinylestradiol component stabilises the uterine lining, while desogestrel suppresses the mid‑cycle surge of luteinising hormone, preventing ovulation. Together they also thicken cervical mucus and alter the endometrium, providing multiple mechanisms that block conception.

The dosing regimen for Mercilon is determined by the prescribing clinician. Typically, it is taken as a daily oral tablet following the specific schedule indicated on the product label, but the exact regimen should be confirmed with a qualified healthcare professional.

Mercilon is intended for use only when pregnancy is not desired. It should not be started during an existing pregnancy, and women who become pregnant while taking it should discontinue use. Breastfeeding mothers should consult their physician, as hormonal contraceptives may affect milk production and infant exposure.

To place an order, submit an enquiry on the Mercilon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mercilon contains desogestrel, a third‑generation progestogen, combined with ethinylestradiol. Compared with older formulations that use levonorgestrel, desogestrel may offer a lower risk of androgenic side effects such as acne, while providing similar contraceptive efficacy. Choice of product should be guided by individual risk factors and physician recommendation.

Mercilon tablets should be stored at room temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Mercilon is taken orally as a tablet, usually once daily at the same time each day. The standard regimen involves a 21‑day active tablet sequence followed by a 7‑day hormone‑free interval, during which withdrawal bleeding typically occurs.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, especially in women with pre‑existing clotting disorders, smokers over 35, or those with uncontrolled hypertension. Rare but severe complications can also involve liver dysfunction, stroke, or severe allergic reactions.

Mercilon is contraindicated in women with a history of thromboembolic disease, known or suspected breast cancer, uncontrolled hypertension, severe liver disease, or those who are pregnant. It should also be avoided by smokers over the age of 35 and individuals with known hypersensitivity to any component of the tablet.